Generalized essential telangiectasia

Summary

Generalized essential telangiectasia (MONDO:0008534) is a disease. A subtype of skin vascular disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	generalized essential telangiectasia
Mondo ID	MONDO:0008534
OMIM	187260
Orphanet	280774
ICD-11	236046211
SNOMED CT	238763007
UMLS	C0406502
MedGen	140803
GARD	0021087
Is cancer (heuristic)	no

Also known as: GET · telangiectasia, generalised essential

Disease family

This is a subtype of skin vascular disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › skin vascular disease › generalized essential telangiectasia

Related subtypes (19): Behcet disease, blue rubber bleb nevus, familial multiple nevi flammei, Sneddon syndrome, cutis marmorata telangiectatica congenita, angioedema, malignant atrophic papulosis, familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome, Maffucci syndrome, Bockenheimer syndrome, calciphylaxis cutis, cutaneous collagenous vasculopathy, Wyburn-Mason syndrome, Cobb syndrome, chilblain lupus, angioma serpiginosum, pityriasis lichenoides, livedo reticularis, atrophic papulosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.